Tag: esophageal cancer

1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe adverse events occurred more frequently in the nivolumab group and more patients withdrew from treatment due to these events. Evidence Rating Level: 1 (Excellent) Study Rundown: The 5-year survival rate of patients...
1. Neoadjuvant chemoradiotherapy (NCRT) with surgery improves the death rate, overall survival, disease-free survival time, and locoregional and distal recurrence rates of advanced esophageal squamous cell carcinoma compared to surgery alone 2. While NCRT incurred more adverse events, there was not more treatment-associated deaths, thus the survival benefit could potentially...
1. Adjuvant nivolumab significantly improved disease-free survival compared to placebo among patients with resected esophageal or gastroesophageal junction cancer. 2. Adverse events were more common in the nivolumab group compared to the placebo group. Evidence Rating Level: 1 (Excellent)     Study Rundown: Neoadjuvant chemotherapy followed by surgery and surveillance is the current standard...
1. A hybrid minimally invasive esophagectomy approach (Ivor-Lewis esophagectomy) was found to have lower rates of intraoperative and postoperative complications after 30 days as compared to an open esophagectomy approach. 2. Disease-free survival and overall survival, though not statistically significant, trended towards higher rates with the minimally invasive hybrid approach. Evidence...
1. A hybrid minimally invasive esophagectomy approach (Ivor-Lewis esophagectomy) was found to have lower rates of intraoperative and postoperative complications after 30 days as compared to an open esophagectomy approach. 2. Disease-free survival and overall survival, though not statistically significant, trended towards higher rates with the minimally invasive hybrid approach. Evidence...